Education
About Us
Working with TipRanks
Follow Us
LifeVantage Corp (LFVN)
NASDAQ:LFVN
Top Page
LifeVantage
(NASDAQ:LFVN)
Rating:71Outperform
Price Target:
$14.50
▲(8.29%Upside)
LifeVantage (LFVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$168.56M
Dividend Yield1.38%
Average Volume (3M)159.89K
Price to Earnings (P/E)19.2
Beta (1Y)-0.22
Revenue Growth8.22%
EPS Growth159.71%
CountryUS
Employees222
SectorConsumer Defensive
Sector Strength55
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.26
Shares Outstanding12,588,183
10 Day Avg. Volume248,910
30 Day Avg. Volume159,893
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)1.58
Price to Sales (P/S)0.00
P/FCF Ratio14.52
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue0.21
Enterprise Value/Gross Profit0.95
Enterprise Value/Ebitda3.56
Forecast
1Y Price Target
$30.00Price Target Upside124.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
LifeVantage Business Overview & Revenue Model
Company DescriptionLifeVantage Corporation (LFVN) is a health and wellness company that focuses on developing and distributing scientifically-backed, high-quality nutraceutical and skin care products. Headquartered in Lehi, Utah, LifeVantage operates primarily in the sectors of dietary supplements and personal care, leveraging expertise in nutrigenomics to offer products that aim to enhance overall wellness and longevity. The company's core offerings include the Protandim line of dietary supplements, TrueScience personal care products, and other wellness-focused items designed to support healthy living.
How the Company Makes MoneyLifeVantage makes money primarily through direct sales and a multi-level marketing (MLM) business model. Revenue is generated from the sale of its nutraceutical and personal care products to both independent distributors and retail customers. The company's distributors purchase products at a wholesale price and sell them at retail prices, earning commissions based on their sales volume. Additionally, distributors are incentivized to recruit new members into their sales network, which can further drive sales and increase commission opportunities. LifeVantage also leverages various partnerships and collaborations to expand its market reach and enhance product distribution, contributing to its revenue streams.
LifeVantage Earnings Call Summary
Earnings Call Date:May 06, 2025
(Q3-2025)
| % Change Since: 12.24%|
Next Earnings Date:Aug 14, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant revenue growth and profitability improvements driven by the successful U.S. launch of the MindBody GLP1 system and ongoing international expansion. However, challenges in international markets and prior stock-out issues have moderated the outlook, leading to a reduced revenue forecast.Q3-2025 Updates
Positive Updates
Revenue Growth
LifeVantage reported third quarter revenues of $58.4 million, marking a 21% increase year-over-year. U.S. revenues grew 31% year-over-year, driven by strong demand for the MindBody GLP1 system.
Profitability Improvements
Adjusted EBITDA increased 27% year-over-year to $6.4 million, with an adjusted EBITDA margin improvement of 50 basis points to 11%. Gross margin also improved by 210 basis points to 81%.
Active Accounts and Subscriptions
Active accounts increased by 17% in the Americas, with a 13% increase in independent consultants and a 19% increase in customers. Subscription orders showed strong growth, with global active templates increasing by over 10,000.
International Expansion
LifeVantage began the international expansion of the MindBody system in Japan, Australia, New Zealand, Mexico, the UK, Europe, and Thailand, with momentum building in these markets.
Successful Product Launch
The launch of the MindBody GLP1 system in the U.S. in October 2024 has been a success with significant sales growth. The product is also being introduced in international markets with promising initial results.
Positive Clinical Study Results
A clinical study revealed that the MindBody GLP1 system increased GLP1 levels in the body by over 200% on average, validating its effectiveness.
Negative Updates
International Revenue Decline
Revenue in international markets decreased by 7% year-over-year, with challenges particularly noted in the Asia Pacific and Europe regions.
Stock-Out Issues
LifeVantage faced stock-out issues with the MindBody GLP1 system after its U.S. launch, affecting customer and consultant satisfaction and contributing to a sequential decline in active accounts.
Lower Revenue Outlook
The company reduced its revenue guidance for fiscal 2025 due to continued challenges in international markets and uncertainties surrounding the international rollout of the MindBody system.
Company Guidance
During the call, LifeVantage provided guidance for fiscal year 2025, projecting revenues between $228 million and $235 million, representing a 16% increase at the midpoint compared to fiscal 2024. The company aims for adjusted EBITDA between $21 million and $24 million, and adjusted non-GAAP earnings per share ranging from $0.72 to $0.88. Additionally, LifeVantage anticipates maintaining strong profitability metrics, including a gross margin of 81% and an effective tax rate of approximately 22% to 24%. The company also highlighted the successful introduction of the MindBody GLP1 system in international markets, which is expected to further drive growth.LifeVantage Financial Statement Overview
Summary
LifeVantage displays solid financial health with robust profitability and efficient cash flow generation. The company has managed to improve its net profit margins and maintain a stable balance sheet. However, moderate revenue growth and the need for greater operational efficiency present opportunities for improvement.Income Statement
LifeVantage's income statement shows a healthy gross profit margin of 80.3% for TTM, indicating efficient cost management. The net profit margin improved to 4.1% from the previous year's 1.5%, reflecting enhanced profitability. Revenue growth is moderate with a TTM increase to $222.3M from $213.4M, a 4.2% growth rate compared to the previous year, highlighting a positive growth trend. However, EBIT and EBITDA margins at 5.8% and 7.3% respectively, though improved, suggest room for operational efficiency gains.75
Positive
Balance Sheet
The balance sheet reveals a solid equity base with an equity ratio of 44.0% in TTM, suggesting a stable financial structure. The debt-to-equity ratio is at a manageable 0.36, indicating conservative leverage. Return on equity is 26.9% for TTM, showing strong returns for shareholders. However, total assets have seen modest growth, and maintaining asset efficiency is crucial for future expansion.70
Positive
Cash Flow
Cash flow analysis indicates robust free cash flow generation in TTM, with a notable free cash flow growth rate of 20.3%. The operating cash flow to net income ratio is 1.47, demonstrating strong cash generation relative to accounting profits. The free cash flow to net income ratio is impressive at 1.31, underscoring the company's ability to convert profits into cash effectively.78
Positive
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 222.35M | 200.16M | 213.40M | 206.36M | 220.18M | 232.91M |
| Gross Profit | 178.53M | 158.72M | 170.01M | 168.26M | 181.99M | 194.95M |
| EBITDA | 16.18M | 7.93M | 4.26M | 9.75M | 23.07M | 19.88M |
| Net Income | 9.15M | 2.94M | 2.54M | 3.12M | 12.89M | 11.55M |
Balance Sheet | ||||||
| Total Assets | 77.24M | 60.30M | 66.12M | 70.71M | 78.73M | 58.88M |
| Cash, Cash Equivalents and Short-Term Investments | 22.47M | 16.89M | 21.61M | 20.19M | 23.17M | 22.14M |
| Total Debt | 12.36M | 13.61M | 13.09M | 15.76M | 18.18M | 1.18M |
| Total Liabilities | 43.23M | 34.31M | 31.47M | 39.19M | 41.92M | 25.62M |
| Stockholders Equity | 34.01M | 25.99M | 34.65M | 31.52M | 36.81M | 33.25M |
Cash Flow | ||||||
| Free Cash Flow | 11.98M | 9.95M | 3.76M | 6.43M | 12.53M | 15.64M |
| Operating Cash Flow | 13.43M | 12.20M | 6.83M | 7.96M | 16.27M | 18.33M |
| Investing Cash Flow | -1.45M | -2.25M | -3.06M | -1.53M | -3.73M | -2.68M |
| Financing Cash Flow | -7.10M | -14.42M | -2.36M | -8.95M | -11.45M | -12.42M |
LifeVantage Technical Analysis
Positive
13.39
Price Trends
12.51
Positive
14.33
Negative
14.85
Negative
Market Momentum
0.05
Negative
59.08
Neutral
83.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Positive. The current price of 13.39 is above the 20-day moving average (MA) of 12.65, above the 50-day MA of 12.51, and below the 200-day MA of 14.85, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 59.08 is Neutral, neither overbought nor oversold. The STOCH value of 83.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFVN.
LifeVantage Risk Analysis
LifeVantage disclosed 50 risk factors in its most recent earnings report. LifeVantage reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LifeVantage Peers Comparison
Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $694.98M | 17.21 | 6.77% | ― | 8.25% | -30.16% | |
77 Outperform | $274.18M | 27.75 | 6.42% | ― | 2.00% | -37.09% | |
72 Outperform | $593.70M | 17.46 | 6.78% | ― | -2.69% | -43.24% | |
71 Outperform | $168.56M | 19.18 | 30.11% | 1.38% | 8.22% | 159.71% | |
71 Outperform | $942.08M | 3.37 | -31.74% | ― | -2.45% | 100.59% | |
65 Neutral | $27.29B | 15.33 | -4.01% | 3.21% | 1.02% | -0.84% | |
44 Neutral | $149.82M | ― | -31.83% | ― | -8.50% | -186.18% |
* Consumer Defensive Sector Average
Performance Comparison
LFVN
LifeVantage
13.39
7.48
126.57%
HLF
Herbalife
9.25
-2.11
-18.57%
NATR
Nature's Sunshine Products
14.85
-0.15
-1.00%
SENEA
Seneca Foods
103.73
43.86
73.26%
HAIN
Hain Celestial
1.66
-5.32
-76.22%
USNA
USANA Health
31.88
-13.09
-29.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.